Blogs
The IL-6 Wars
In the years to come, the availability of numerous new IL-6 inhibitors it will either complicate treatment decisions, alter existing treatment paradigms, or result in an all-out war against TNF inhibitor dominance. Data, differences and time will tell.
Cannabis Arteritis
KOLs Predict: What Will the Next Year Bring?
A new subspecialty may emerge. New drugs will be approved (but it will be difficult for patients to get coverage for them). And an American team will win the World Series. All these and more: here are predictions for 2017 and beyond from rheumatologists across the country and around the world.
A Winning Season*
Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.
Hot Stuff Part IV: Cardiovascular Outcomes and Vasculitis
The last in a four-part series from the CCF's Biologic Therapies Summit, we examine how to reduce CV risks in practice plus the current status of vasulitis management and the role biologics may play.